OBJECTIVES: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is an ongoing 18 months prospective observational study with the objective of estimating resource use and health related quality of life related to osteoporotic fractures. This study aims to describe the resource utilization after vertebral fracture sustained during 2007-2012 pooled from nine countries: Australia, Austria, France, Italy, Lithuania, Mexico, Russia, and the UK. METHODS: Patients studied were ≥ 50 years and lived at home prior to fracture. Data were collected through patient interviews and review of medical records: at baseline, 12, 18, and 28 months after fracture. Only resource use related to the fracture event was collected. RESULTS: There were 636, 572, and 536 patients available for analysis at 4, 12, and 18 months follow-up, respectively. The mean age (±SD) at fracture was 70±10 years and 81% were women. 45% of patients were hospitalized. Mean hospital length of stay (±SD) was 5.7±12.4 days during months 0-4 and 9.6±9.8 during months 5-18. The mean number of physician visits (±SD) was 2.8±2.7 during months 0-4 and 1.9±3.6 months 5-18. The mean number of nurse visits (±SD) was 1.4±6.5 and 1.5±19.9 during the corresponding periods, respectively. During months 0-4, 72% of patients used analgesics, 59% calcium, vitamin D, and 41% pharmacological interventions for osteoporosis. The respective uptakes for months 5-18 were 56%, 55% and 34%. CONCLUSIONS: The majority of health care consumed was related to vertebral fracture during the first 4 months but substantial consumption persists up to 18 months after fracture.

PM545 CARE UTILIZATION PATTERNS ASSOCIATED WITH ONSITE VERSUS OFFSITE CHIROPRACTIC CARE

Endermann L1, Hou Q2, Miller RM2
1Cerner Research, Cerner Corporation, Omaha, NE, USA, 2Cerner Research, North Kansas City, MO, USA, *Cerner Health Connections, Cerner City, CA, USA

OBJECTIVES: Musculoskeletal conditions are the primary cause of physical disability in the United States, and have implications for workplace productivity and employer health costs. This study determined the influence of employer-sponsored, onsite chiropractic care on health care utilization. METHODS: A retrospective claims analysis of members of an employer-sponsored health plan receiving chiropractic care exclusively onsite or offsite from 2010-2012. Employer's health benefits administration program. Eligible participants had continuous enrollment in the health plan and ≥1 billing code for chiropractic services during the 36-month study period. Utilization was assessed in 2 categories: radiological procedures and clinical care. Utilization differences were evaluated by having ≥1 health care event in any category. Continuous variables were summarized as means, and binary variables as counts and proportions. Differences were assessed using the 2-sample t-tests for categorical variables and t-test for continuous variables. Comparisons were considered significant at alpha = 0.05. RESULTS: The analysis included 876 onsite and 759 offsite participants. The population was similar in gender; the onsite group was slightly younger. The offsite group received more radiology services overall (55.5% vs 38.2%, P<0.001) including x-ray (46.0% vs 26.6%, P<0.001); ultrasound (15.8% vs 10.7%, P<0.0001), and magnetic resonance imaging (24.6% vs 12.4%, P<0.0001); had higher outpatient (47.3% vs 30.2%, P<0.0001) and emergency department (19.0% vs 13.1%, P=0.022) utilization, and demonstrated greater use of chiropractic care (mean 15.2 vs 9.16 visits; P<0.0001) and physical therapy (mean 9.6 vs 1.5 visits; P<0.0001). CONCLUSIONS: In patients receiving chiropractic care, those utilizing onsite services had lower health care utilization, including radiology services , clinical care, and counts of chiropractic and physical therapy services. The study results support the value of chiropractic services offered at onsite health centers, where more tightly managed and evidence-based approaches to musculoskeletal conditions can be facilitated.

PM546 HEALTH CARE RESOURCE UTILIZATION IN THE MANAGEMENT OF KNEE OSTEARTHROSIS WITH HYALURONIC ACID IN A CANADIAN REAL-WORLD POPULATION

Petriček M1, DuChane J2, Miller R.M1
1University of Western Ontario, London, ON, Canada, 2Premier Research, Naperville, IL, USA

OBJECTIVES: To examine the health care resource utilization in patients with knee osteoarthritis and treated with Hylan G-F 20 (Synvisc, Genzyme Biosurgery) compared with patients treated with alternative intra-articular hyaluronic acid (HA) injections in Ontario, Canada. METHODS: This is an observational, prospective cohort of patients 18 years and older who, between June 1, 1999 and December 31, 2012 had: 1) a diagnosis of knee osteoarthritis identified by ICD-9-10 or text coding; 2) received at least 1 treatment cycle with intra-articular HA and; 3) complete pain and mobility data for each treatment cycle. Data from the Southwestern Ontario (SWO) database, has been continuously compiled since 1999 and includes demographic, biometric, laboratory, diagnostic and health resource measures as collected in a primary care setting. Health care resource utilization included clinic visits, emergency visits, hospitalizations, home care visits, knee bracing, radiographs, and work absenteeism. Differences between treatments were compared using independent sample t-tests. RESULTS: 6,618 patients met all inclusion criteria of which 44% were treated with Hylan G-F 20. Patients were similar across treatment groups. During the follow-up period, patients received, on average, 6 HA treatment cycles and an annual knee X-ray, with 44% of them needing a knee brace during this period. During the study period there were 6,705 osteoarthritis-related hospitalizations, and over 10,000 combined physiotherapy/PT/occupational therapy (OT) and home care nursing visits among patients prescribed HA. Hylan G-F 20 patients had fewer visits to a GP (36%) and specialist (39%), lower use of PT/OT (23% and 1%) and home care nursing (26%) compared to other HA treatments (p<0.05 for all comparisons). CONCLUSIONS: This analysis demonstrates that not all HA injections in patients with knee osteoarthritis represent similar resource utilization. Further research world examination of the effectiveness of HA for reducing clinical symptoms and improving health care resource utilization in knee osteoarthritis is warranted.

PM547 THE RELATIONSHIP BETWEEN ADHERENCE AND HEALTH CARE COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE CASE COMPARISON STUDY

Clark B1, Duchane J2, Miller R.M1
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Premier Research, Naperville, IL, USA

OBJECTIVES: The objective of this research report was to determine the relationship between medication adherence levels and health care cost among patients with rheumatoid arthritis (RA). METHODS: This study used a retrospective case comparison design to examine per member per month (PMPM) medical cost. The commercial population of patients with RA was extracted from two large claims data bases between years 2006 and 2009. The case cohort consisted of compliant patients (MPR ≥80%) receiving medication management from the Specialty division of a large pharmacy retail chain. The comparison cohort consisted of non-compliant patients (MPR <80%) from a national benchmark pharmacy and medical claims database. Using propensity scores, patients were matched on age, gender, risk score, socio-economic status, standard industrial classification code, comorbidity conditions, and pre-medication gap. This process resulted in 512 one-to-one match pairs. RESULTS: Patients with RA who were compliant to their medication regimen had 25% lower PMPM medical cost (in-patient, out-patient, professional, and emergency room cost) than patients who were non-compliant ($637 vs. $855 respectively; Δ=0.4058). The major cost this difference was due in in-patient cost which was 16% lower for compliant patients, followed by professional cost which was 15% lower for compliant patients. A closer look at medical cost by levels of compliance reveals that medical cost decreased at each level of medication compliance described below. Patients with adherence levels less than 40% had PMPM cost of $1024, those with adherence levels between 40% and 80% had PMPM cost of $838, and patients with adherence levels greater than or equal to 80% had PMPM cost of $637. CONCLUSIONS: Medication cost decreases as adherence to the RA medication regimen increases. Given that the cost of treating RA can be extremely expensive, one approach to addressing this financial issue is to target medication adherence.

PM548 WITHDRAWN

MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PM549 COLONIC UTILIZATION PATTERNS AND REFILL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

Hills J1, Kolse S1, Rice P2
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Premier Research, Naperville, IL, USA

OBJECTIVES: This study used a retrospective claims analysis of members of an employer-sponsored health plan receiving drugs for the treatment of inflammatory bowel disease (IBD) and patients who delayed their first dose of the drug for 30 days or longer.

METHODS: The comparison cohort consisted of patients with IBD who were treated with either infliximab (Ib), adalimumab (Ad), or certolizumab pegol (Cz). The comparison design to examine per member per month (PMPM) medical cost. The commercial population of patients with IBD was extracted from two large claims databases between years 2006 and 2009. The case cohort consisted of compliant patients (MPR ≥80%) receiving medication management from the Specialty division of a large pharmacy retail chain. The comparison cohort consisted of non-compliant patients (MPR <80%) from a national benchmark pharmacy and medical claims database. Using propensity scores, patients were matched on age, gender, risk score, socio-economic status, standard industrial classification code, comorbidity conditions, and pre-medication gap. This process resulted in 512 one-to-one match pairs.

RESULTS: Patients with RA who were compliant to their medication regimen had 25% lower PMPM medical cost (in-patient, out-patient, professional, and emergency room cost) than patients who were non-compliant ($637 vs. $855 respectively; Δ=0.4058). The major cost this difference was due in in-patient cost which was 16% lower for compliant patients, followed by professional cost which was 15% lower for compliant patients. A closer look at medical cost by levels of compliance reveals that medical cost decreased at each level of medication compliance described below. Patients with adherence levels less than 40% had PMPM cost of $1024, those with adherence levels between 40% and 80% had PMPM cost of $838, and patients with adherence levels greater than or equal to 80% had PMPM cost of $637.

CONCLUSIONS: Medication cost decreases as adherence to the RA medication regimen increases. Given that the cost of treating RA can be extremely expensive, one approach to addressing this financial issue is to target medication adherence.

PM548 WITHDRAWN